Skip to main content
Premium Trial:

Request an Annual Quote

BGI Receives CE Mark for NIFTY Noninvasive Prenatal Test on BGISEQ-500 Platform

NEW YORK (GenomeWeb) – BGI has received the CE mark for its NIFTY cell-free DNA-based noninvasive prenatal test kit for fetal chromosomal aneuploidies on the BGISEQ-500 sequencing platform, the company said last week.

The test obtained EU medical device CE certification, issued by the British Standards Institution (BSI).

The NIFTY test estimates the risk of a fetus having trisomy 21, trisomy 18, and trisomy 13, sex chromosomal disorders, and certain deletion syndromes. It works by analyzing cell-free DNA from maternal blood at 10 weeks of gestation.

The China Food and Drug Administration had also previously accredited both the NIFTY test and the BGISEQ platform.

"By being able to offer the NIFTY test on our own BGISEQ-500 platform, rather than relying on third party sequencing platforms, we are able to improve our cost efficiency and ensure total quality control of the entire testing process," Ryan Liu, Europe sales director for BGI Genomics, said in a statement.

BGI said that as of the end of 2017, the NIFTY test has been performed on more than 2.5 million samples worldwide. 

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.